| Expression pattern: |
UP |
| Associated gene: |
NOVA2, Ago2 |
| Associated microRNA: |
miR-635 |
| Biological function: |
Promotes NSCLC malignant progression by enhancing proliferation and angiogenesis and inhibiting apoptosis; promotes tumor growth in vivo. |
| Molecular mechanism: |
Acts as a miRNA sponge (ceRNA) for miR-635 to increase NOVA2 expression and activate the PI3K/AKT signaling pathway. |
| Biological pathway or process: |
PI3K/AKT (promotes); proliferation (promotes); angiogenesis (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
divergent primers PCR; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; RT-qPCR; Clinical Sample Validation; Transfection; CCK8; EdU Staining; Colony Formation Assay; Tube Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
circ_0102231 expression was significantly associated with TNM stage, lymph node metastasis and distant metastasis of NSCLC. |
| Description: |
circ_0102231 is up-regulated in NSCLC tissues/cells and is associated with advanced clinicopathological features. Functionally, circ_0102231 promotes NSCLC proliferation and angiogenesis and suppresses apoptosis, and its knockdown inhibits xenograft tumor growth. Mechanistically, circ_0102231 acts as a ceRNA sponge for miR-635 to derepress NOVA2 and activate PI3K/AKT signaling. |
| Confidence score: |
0.8327 |